Jubilant Pharmova Ltd says preliminary Phase 1 JBI-802 data, including platelet responses in all 8 patients at 15 mg, were selected for oral presentation at ASH.
- As of June 30, 2026, all 8 patients treated at 15 mg achieved a platelet reduction of more than 50% or platelet normalization by Week 3; median time to response was 15 days.
- Platelet normalization continued through 33–46 weeks in patients with more than 12 weeks of follow-up; 7 of 11 patients with leukocytosis achieved complete hematologic response.
- No dose-limiting toxicities were observed at 5, 7 or 15 mg; further efficacy, safety and molecular data are planned for the 68th ASH Annual Meeting.